Cas No.: | 65836-72-8 |
Chemical Name: | 2-Chloro-N-(3,4-dimethoxybenzyl)acetamide |
Synonyms: | 2-Chloro-N-(3,4-dimethoxybenzyl)acetamide;2-chloro-N-[(3,4-dimethoxyphenyl)methyl]acetamide;2-Chloro-N-((3,4-dimethoxyphenyl)methyl)acetamide;Acetamide,2-chloro-N-((3,4-dimethoxyphenyl)methyl);C-Chlor-N-veratryl-acetamid;Chlor-essigsaeure-veratrylamid;chloro-acetic acid veratrylamide;N-(3.4-Dimethoxy-benzyl)-chloracetamid;N-(Dimethoxy-3,4 benzyl)-chloroacetamide [French];N-Chloracetyl-(3,4-dimethoxyphenyl)methylamin;N-chloroacetyl-3,4-dimethoxybenzylamine;DKM 2-93 |
SMILES: | O=C(NCC1=CC=C(OC)C(OC)=C1)CCl |
Formula: | C11H14NO3Cl |
M.Wt: | 243.68676 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | DKM 2-93 is a relatively selective inhibitor of UBA5 with an IC50 of 430 μM. |
In Vivo: | DKM 2-93 daily treatment significantly impairs tumor growth of PaCa2 cells in vivo in tumor xenograft studies in immune-deficient mice without causing any weight loss or overt toxicity[1]. |
In Vitro: | Ubiquitin-like modifier activating enzyme 5 (UBA5) is a novel pancreatic cancer therapeutic target. DKM 2-93 impairs pancreatic cancer cell survival through covalently modifying the catalytic cysteine of UBA5, thereby inhibiting its activity as a protein that activates the ubiquitin-like protein UFM1 to UFMylate proteins. DKM 2-93 inhibits PaCa2 and Panc1 cells survival with IC50s of 90 and 30 μM, respectively[1]. |
Cell Assay: | PaCa2 and Panc1 cells are treated with 0-1000 μM DKM 2-93 for 48 hours. Cell viability is assessed by Hoescht stain[1]. |
Animal Administration: | Mice: Mice are subcutaneously injected with PaCa2 cells to initiate the tumor xenograft study and treatments of mice are initiated with vehicle or DKM 2-93 (50 mg/kg ip, once per day) three days after injection of cancer cells[1]. |
References: | [1]. Roberts AM, et al. Chemoproteomic Screening of Covalent Ligands Reveals UBA5 As a Novel Pancreatic Cancer Target. ACS Chem Biol. 2017 Apr 21;12(4):899-904. |